



# Human Anti-Evolocumab monoclonal antibody, clone AbD40405ia (CABT-ZB1172)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Specificity</b>	Evolocumab
<b>Target</b>	Evolocumab
<b>Immunogen</b>	Evolocumab
<b>Isotype</b>	IgG1, $\lambda$
<b>Source/Host</b>	Human
<b>Species Reactivity</b>	N/A
<b>Clone</b>	AbD40405ia
<b>Affinity Constant</b>	The monovalent intrinsic affinity of AbD40405ia was measured as $K_D = 5$ nM by real time, label free molecular interaction analysis on immobilized evolocumab.
<b>Purification</b>	Protein A purified
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	Suitable for use in ADA bridging ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
<b>Format</b>	Liquid
<b>Concentration</b>	Lot specific
<b>Size</b>	100 $\mu$ g

<b>Buffer</b>	PBS
<b>Preservative</b>	0.01% Thiomersal
<b>Storage</b>	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
<b>Ship</b>	Wet ice

## BACKGROUND

<b>Introduction</b>	Evolocumab (Repatha) is a fully human IgG2 lambda antibody developed using transgenic mouse technology. It has been approved for treating selected patients with high cholesterol, and for the prevention of heart attack and stroke. The drug prevents the PCSK9 protein binding to the low density lipoprotein receptor (LDLR), thereby increasing the number of LDLRs available and lowering LDL levels.
<b>Keywords</b>	Evolocumab; Repatha